Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
    • CHEST 2021
    • IDWeek 2021
    • IAS 2021
    • ADA 2021
    • ATS 2021
    • ACC 2021
    • ACP 2021
    • AAN 2021
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
    • CHEST 2021
    • IDWeek 2021
    • IAS 2021
    • ADA 2021
    • ATS 2021
    • ACC 2021
    • ACP 2021
    • AAN 2021

Geriatrics

  • You have access
    Bone turnover markers to monitor oral bisphosphonate therapy
    CME article
    Nikita Ashcherkin, MD, Archna A. Patel, MD, MPH, Alicia Algeciras-Schimnich, PhD and Krupa B. Doshi, MD, FACE
    Cleveland Clinic Journal of Medicine January 2023, 90 (1) 26-31; DOI: https://doi.org/10.3949/ccjm.90a.22002

    Rapid changes in levels of bone turnover markers can be useful in monitoring the effectiveness of therapy and improving adherence to therapy.

  • You have access
    Making best use of bone turnover markers to monitor oral bisphosphonate therapy
    Sarah Keller, MD
    Cleveland Clinic Journal of Medicine January 2023, 90 (1) 32-34; DOI: https://doi.org/10.3949/ccjm.90a.22092

    Clinical applications of bone turnover markers can include determining when to start or end a bisphosphonate “holiday” and measuring treatment response.

  • You have access
    Geriatric update 2022: Preventing Alzheimer disease and more
    Melissa Morgan-Gouveia, MD, Kathleen Drago, MD, FACP, Patricia Harris, MD, MS and Meera Sheffrin, MD, MAS
    Cleveland Clinic Journal of Medicine November 2022, 89 (11) 617-624; DOI: https://doi.org/10.3949/ccjm.89a.21094

    Key topics include Alzheimer dementia, effects of frailty and social isolation, COVID-19 risks in patients with dementia, hospital-at-home programs, deprescribing antihypertensive drugs, bisphosphonate-related fractures, and cannabis use.

  • You have access
    Managing stage 1 hypertension: Consider the risks, stop the progression
    Abel Hooker, MD, Kevin G. Buda, DO and Maarya Pasha, MD
    Cleveland Clinic Journal of Medicine May 2022, 89 (5) 244-248; DOI: https://doi.org/10.3949/ccjm.89a.21101

    Guidelines on managing patients with stage 1 hypertension and a low 10-year risk of atherosclerotic cardiovascular disease.

  • You have access
    Palliative care: An update for internists
    Rachel D. Havyer, MD, FAAHPM, Nauzley Abedini, MD, MSc, Robert L. Jayes, MD, Brenda Matti-Orozco, MD, Daniel H. Pomerantz, MD, MPH and Aziz A. Ansari, DO, SFHM, FAAHPM, FACP
    Cleveland Clinic Journal of Medicine May 2022, 89 (5) 262-268; DOI: https://doi.org/10.3949/ccjm.89a.21075

    A review of recent research to guide symptom management, advance-care planning, and communication training to maximize compassionate care.

  • You have access
    Treating anemia: It’s not just the EPO
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine April 2022, 89 (4) 174-175; DOI: https://doi.org/10.3949/ccjm.89b.04022

    Long-term effects of treatment with the new oral inhibitors of prolyl hydroxylase will need to be carefully monitored, as prolyl hydroxylase is a key structural component of diverse proteins.

  • Anemia of chronic kidney disease: Will new agents deliver on their promise?
    You have access
    Anemia of chronic kidney disease: Will new agents deliver on their promise?
    Tarek Souaid, MD, Jonathan Taliercio, DO, James F. Simon, MD, MBA, Ali Mehdi, MD, MEd and Georges N. Nakhoul, MD, MEd
    Cleveland Clinic Journal of Medicine April 2022, 89 (4) 212-222; DOI: https://doi.org/10.3949/ccjm.89a.21100

    A review of the pathophysiology of anemia of chronic kidney disease, major clinical trials, and novel therapies.

  • You have access
    Potential systemic benefits of shocking or blocking nerves
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine March 2022, 89 (3) 119-120; DOI: https://doi.org/10.3949/ccjm.89b.03022

    What has really caught my attention is the expanding research on controlled regional neuromodulation and its impact on systemic physiology and inflammation.

  • Stellate ganglion block as a treatment for vasomotor symptoms: Clinical application
    You have access
    Stellate ganglion block as a treatment for vasomotor symptoms: Clinical application
    Yeonsoo Sara Lee, BS, Christopher Wie, MD, Scott Pew, MD and Juliana M. Kling, MD, MPH
    Cleveland Clinic Journal of Medicine March 2022, 89 (3) 147-153; DOI: https://doi.org/10.3949/ccjm.89a.21032

    Hormone therapy is the mainstay of treatment, but there is a clear need for safe and effective nonhormonal options. The authors review data on the use of stellate ganglion block in perimenopausal and postmenopausal patients.

  • You have access
    Hypercalcemia and vitamin A: A vitamin to keep in mind
    Saif Munther Borgan, MD, Leila Zeinab Khan, MD and Vinni Makin, MD, FACE
    Cleveland Clinic Journal of Medicine February 2022, 89 (2) 99-105; DOI: https://doi.org/10.3949/ccjm.89a.21056

    Vitamin A toxicity can affect bone resorption and hypercalcemia and should be explored in unexplained cases of parathyroid hormone-independent hypercalcemia.

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 16
  • Adolescent Medicine
  • Allergy/Immunology
  • Anticoagulation
  • Cardiology
  • Covid-19
  • Critical Care
  • Dermatology
  • Diabetes
  • Drug Therapy
  • Electrophysiology
  • Emergency Medicine
  • Endocrinology
  • Family Medicine
  • Gastroenterology
  • Genetics
  • Geriatrics
  • Hematology
  • Hepatology
  • Hospice & Palliative Medicine
  • Hospital Medicine
  • Imaging
  • Infectious Diseases
  • Medical Humanities/Ethics
  • Medical Humanities/Ethics
  • Men's Health
  • Mental Health
  • Nephrology
  • Neurology
  • Obesity
  • Oncology
  • Pain
  • Physical Exam
  • Practice Management
  • Preventive Care
  • Pulmonology
  • Rehabilitation Medicine
  • Rheumatology
  • Sleep Medicine
  • Surgery/Surgery Subspecialties
  • Vascular Medicine
  • Women's Health

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2023 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire